ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

NI Communications Effort, Saves By Congress, Now A Major National Cancer Program Resource

August 15, 1975

FDA Updates Safety Information for 5-Alpha Reductase Inhibitors

June 17, 2011

Reed To Leave NCI Next Year; Allegra Moves To Extramural Side; Ozer Heads Okla. Center.

July 21, 2000

Treatment IND or GM-CSF Is Approved

October 5, 1990

DCT Board Approves Concept of New Programs, Including “Task Order”

November 2, 1979

No Justification Provided: AAUP Demands Reinstatement of Faculty Denied Tenure Renewal at MD Anderson

May 16, 2014